Home > Products > HER3 & IGF1R > Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (Fab-IgG)

Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (Fab-IgG)  (CAT#: FABIG-169)

Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Pancreatic cancer; Hepatocellular carcinoma (HCC) therapy.
Datasheet INQUIRY

Specifications

Targets
HER3 & IGF1R
Type
Fab-IgG
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Pancreatic cancer; Hepatocellular carcinoma (HCC)

Targets

Target 1
HER3
Gene ID
UniProt ID
Alternative Names
ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
Target 2
IGF1R
Gene ID
UniProt ID
Alternative Names
IGF1R; insulin-like growth factor 1 receptor; IGFR; CD221; IGFIR; JTK13; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "HER3 & IGF1R"
See other bsAb targets related to "IGF1R"

See other bsAb targets related to "HER3"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (Fab-IgG) (FABIG-169). Click the button below to contact us or submit your feedback about this product.